原发性肝癌患者血清IGF-Ⅰ、AFU、AFP、CA199检测的临床意义

Clinical Significance of Determination of Changes of Serum IGF-Ⅰ,AFU,AFP and CA199 Contents in Patients with Primary Liver Cancer

目的探讨了原发性肝癌患者血清IGF-Ⅰ、AFU、AFP、CA199水平及意义。方法分别应用放免法和生化法对38例原发性肝癌患者血清的IGF-Ⅰ、AFU、AFP、CA199检测,并与30名正常人作比较。结果原发性肝癌患者血清中IGF-Ⅰ、AFU、AFP、CA199水平显著地高于正常人组(P<0.01)。IGF-Ⅰ、AFU、AFP、CA199四项指标对原发性肝癌的阳性率分别为84.2%、78.9%、73.6%、81.5%。IGF-Ⅰ+AFU、IGF-Ⅰ+AFP、IGF-Ⅰ+CA199、IGF-Ⅰ+AFU+AFP+CA199联检的阳性率分别为86.8%、89.5%、92.1%、97.4%。结论联检血清IGF-Ⅰ、AFU、AFP、CA199可提高对原发性肝癌的诊断阳性率。

Objective To investigate the changes of serum IGF - Ⅰ , AFU, AFP and CA199 contents in patients with primary liver cancer. Methods Serum IGF - Ⅰ , AFP, CA199 levels were measured with R1A and AFU levels were measured with biochemistry method in 38 patients with primary liver cancer and 30 controls. Results The serum IGF - Ⅰ , AFU, AFP, CA199 levels were significantly higher in the patients than those in controls （P 〈0.01 ）. The positive rates of IGF - Ⅰ , AFU, AFP and CA199 in patients with primary liver cancer were 84.2%, 78.9%, 73, 6% and 81.5% respectively. Positive rates with combined measurement of IGF- Ⅰ plusAFU, IGF- Ⅰ plusAFP, IGF- Ⅰ plus CA199 and IGF- Ⅰ plus AFU, AFP, CA199 were 86.8%, 89.5%, 92. 1%, 97.4% respectively. Conclusion Combined measurement of IGF - Ⅰ , AFU, AFP and CA199 can significantly increase the positive rate in the diagnosis of primary, liver cancer.